Clinical Trial Update: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b [Phase 1]

View source ↗

Summary

This update reports a first-in-human Phase 1 study of the tuberculosis vaccine candidate H107e/CAF®10b, sponsored by Statens Serum Institut, which is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• H107e/CAF®10b (Tuberculosis vaccine candidate H107e with CAF10b adjuvant)

Snippet

Sponsor: Statens Serum Institut | Conditions: Healthy | Phase 1 | Status: ACTIVE_NOT_RECRUITING